Convalescent Plasma Samples
SARS-CoV-2 infection, Pneumonia
CORONAVIRUS DISEASE 2019, SARS-COV-2 INFECTION, MAY, PNEUMONIA, CORONAVIRUS, SEVERE ACUTE RESPIRATORY SYNDROME
The REMAP-CAP panel included 67 plasma samples collected during April to May 2020 from SARS-CoV-2–infected blood donors ≥28 days after resolution of their symptoms in England (ClinicalTrials.gov NCT02735707 [Comparison of REMAP-CAP and Argentinian Plasma and Trial as Well as Convalescent Plasma From Vaccinated IndividualsAbbreviations: CI, confidence interval; COVID-19, coronavirus disease 2019; CP, convalescent plasma; ICU, intensive care unit; Ig, immunoglobulin; IQR, interquartile range; nAb, neutralizing antibody; REMAP-CAP, Randomized Embedded Multifactorial Adaptive Platform for Community Acquired Pneumonia; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.The Argentina panel included 61 plasma samples collected during June to October 2020 in Argentina ≥3 days after resolution of SARS-CoV-2 symptoms which had lasted ≥10 days; these donors also had 2 negative reverse transcription polymerase chain reaction (RT-PCR) results prior to donation (ClinicalTrials.gov NCT04479163 [The vaccine panel included 102 plasma samples obtained during April to August 2021 from UK blood donors who had had a previous SARS-CoV-2 infection (range, 92–473 days prior to sampling, median 310 days, estimated based on the earliest seropositive prevaccine sample) followed by vaccination (range, 40–346 days before sampling, median 178 days [